These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32798333)

  • 1. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
    Mollenhauer B; Dakna M; Kruse N; Galasko D; Foroud T; Zetterberg H; Schade S; Gera RG; Wang W; Gao F; Frasier M; Chahine LM; Coffey CS; Singleton AB; Simuni T; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Marek K; Siderowf A; Cedarbaum JM; Hutten SJ; Trenkwalder C; Graham D
    Mov Disord; 2020 Nov; 35(11):1999-2008. PubMed ID: 32798333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Wilke C; Dos Santos MCT; Schulte C; Deuschle C; Scheller D; Verbelen M; Brockmann K; von Thaler AK; Sünkel U; Roeben B; Bujac S; Metzger FG; Maetzler W; da Costa AN; Synofzik M; Berg D
    Mov Disord; 2020 Jul; 35(7):1233-1238. PubMed ID: 32338403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
    Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
    Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light levels predict clinical progression and death in multiple system atrophy.
    Chelban V; Nikram E; Perez-Soriano A; Wilke C; Foubert-Samier A; Vijiaratnam N; Guo T; Jabbari E; Olufodun S; Gonzalez M; Senkevich K; Laurens B; Péran P; Rascol O; Le Traon AP; Todd EG; Costantini AA; Alikhwan S; Tariq A; Ng BL; Muñoz E; Painous C; Compta Y; Junque C; Segura B; Zhelcheska K; Wellington H; Schöls L; Jaunmuktane Z; Kobylecki C; Church A; Hu MTM; Rowe JB; Leigh PN; Massey L; Burn DJ; Pavese N; Foltynie T; Pchelina S; Wood N; Heslegrave AJ; Zetterberg H; Bocchetta M; Rohrer JD; Marti MJ; Synofzik M; Morris HR; Meissner WG; Houlden H
    Brain; 2022 Dec; 145(12):4398-4408. PubMed ID: 35903017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
    Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY
    Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
    Bartl M; Dakna M; Schade S; Otte B; Wicke T; Lang E; Starke M; Ebentheuer J; Weber S; Toischer K; Schnelle M; Sixel-Döring F; Trenkwalder C; Mollenhauer B
    Mov Disord; 2023 Jan; 38(1):68-81. PubMed ID: 36267007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
    Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-linked Dystonia-Parkinsonism.
    Al Ali J; Vaine CA; Shah S; Campion L; Hakoum A; Supnet ML; Acuña P; Aldykiewicz G; Multhaupt-Buell T; Ganza NGM; Lagarde JBB; De Guzman JK; Go C; Currall B; Trombetta B; Webb PK; Talkowski M; Arnold SE; Cheah PS; Ito N; Sharma N; Bragg DC; Ozelius L; Breakefield XO
    Mov Disord; 2021 Jan; 36(1):206-215. PubMed ID: 32975318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood neurofilament light chain in Parkinson's disease.
    Buhmann C; Magnus T; Choe CU
    J Neural Transm (Vienna); 2023 Jun; 130(6):755-762. PubMed ID: 37067597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.